Medipal Holdings Corp
Medipal Holdings's GHG Emissions Data Preview
In 2023, Medipal Holdings completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Medipal Holdings has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Medipal Holdings's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Medipal Holdings amounted to 74,991 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Medipal Holdings decreased by 1.44%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Medipal Holdings's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Medipal Holdings's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Medipal Holdings were 28,439 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Medipal Holdings reduced its Scope 1 emissions over time?
Since 2018, Medipal Holdings's Scope 1 emissions have decreased by 21.1%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Medipal Holdings's Scope 1 emissions decreased by 5.81%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Medipal Holdings's Scope 2 emissions?
In 2023, Medipal Holdings reported Scope 2 greenhouse gas (GHG) emissions of 46,552 tCOâ‚‚e without specifying the calculation method.
Has Medipal Holdings reduced its Scope 2 emissions over time?
Since 2018, Medipal Holdings's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 11.49%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Medipal Holdings's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Medipal Holdings 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Medipal Holdings use for Scope 2 reporting?
In 2023, Medipal Holdings reported its Scope 2 emissions using an unspecified methodology.
Medipal Holdings's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Medipal Holdings's Value Chain Emissions
In 2023, Medipal Holdings reported 14,255,621 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Medipal Holdings includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, up from 1 in 2022, reflecting improved emissions accounting practices and greater transparency across the company's value chain
Medipal Holdings's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Medipal Holdings's Scope 3 emissions?
In 2023, Medipal Holdings reported total Scope 3 emissions of 14,255,621 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 95.68% of these emissions originated from upstream activities such as purchased goods and capital goods, while 4.32% came from downstream activities like product use, distribution, and end-of-life treatment.
Has Medipal Holdings reduced its Scope 3 emissions over time?
Since 2018, Medipal Holdings's Scope 3 emissions have increased by 43,688%, reflecting a rising long-term trend in Scope 3 emissions over time.
Compared to the previous year (2022), Medipal Holdings's Scope 3 emissions increased by 36,561.92%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Medipal Holdings disclose?
In 2023, Medipal Holdings reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Medipal Holdings's Scope 3 emissions?
In 2023, the largest contributors to Medipal Holdings's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 13,426,666 tCOâ‚‚e (94.19%)
- End-of-Life Treatment of Sold Products (Cat. 12): 581,582 tCOâ‚‚e (4.08%)
- Upstream Transportation and Distribution (Cat. 4): 110,073 tCOâ‚‚e (0.77%)
Medipal Holdings's Scope 3 Emissions by Categories
Insights into Medipal Holdings's Total Carbon Footprint
In 2023, Medipal Holdings reported a total carbon footprint of 14,330,612 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12,364.87% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Medipal Holdings's total carbon footprint was Scope 3 emissions, accounting for 99.48% of the company's total carbon footprint, followed by Scope 2 emissions at 0.32%.